These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15889669)

  • 1. [Hormone resistance and its modulation in breast cancer].
    Kahán Z; Thurzó L
    Orv Hetil; 2005 Apr; 146(16):731-7. PubMed ID: 15889669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
    Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
    Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
    Schiff R; Massarweh S; Shou J; Osborne CK
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
    Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
    Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
    Nicholson RI; Hutcheson IR; Hiscox SE; Knowlden JM; Giles M; Barrow D; Gee JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S29-36. PubMed ID: 16113097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective estrogen receptor modulators. An aid in unraveling the links between estrogen and breast cancer.
    Fuqua SA; Russo J; Shackney SE; Stearns ME
    Postgrad Med; 2001 Mar; Spec No():3-10. PubMed ID: 11296736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
    Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK; Marquez-Garban DC; Pietras RJ
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
    Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells.
    Kilker RL; Hartl MW; Rutherford TM; Planas-Silva MD
    J Steroid Biochem Mol Biol; 2004 Sep; 92(1-2):63-71. PubMed ID: 15544931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy.
    Nicholson RI; Staka C; Boyns F; Hutcheson IR; Gee JM
    Endocr Relat Cancer; 2004 Dec; 11(4):623-41. PubMed ID: 15613443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.
    Staka CM; Nicholson RI; Gee JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S85-97. PubMed ID: 16113102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
    Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
    Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.
    Pietras RJ
    Oncologist; 2006; 11(7):704-17. PubMed ID: 16880230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
    Osborne CK; Schiff R; Arpino G; Lee AS; Hilsenbeck VG
    Breast; 2005 Dec; 14(6):458-65. PubMed ID: 16236516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.